Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).

NCT05252468 is registered in ClinicalTrials.gov with Nasus Pharma as lead sponsor.

NCT NCT05252468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05252468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
Lead sponsor
Nasus Pharma
Phase
Not applicable
Overall status
Completed
Start date
May 19, 2021
Completion date
December 2, 2021
Enrollment
693 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, upper respiratory tract infections